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ABSTRACT: A novel macrocyclic construct consisting of a pyrazolopyrimidine scaﬀold concatenated to a benzene ring
through two triazoles has been developed to investigate uncharted chemical space with bioactive potential. The 18-atom
macrocycle was assembled via a double copper-catalyzed alkyne−azide cycloaddition (CuAAC) reaction between 1,3-
bis(azidomethyl)benzene and a bis-propargylated pyrazolo[3,4-d]pyrimidine core. The resulting macrocycle was functionalized
further into a multicyclic analog that displays selective inhibitory activity against the receptor tyrosine kinase AXL.
■ INTRODUCTION
Molecules featuring a ring of 12 or more atoms are formally
known as macrocycles. Enabled by their unique structural
characteristics, diﬀerent macrocyclic compounds, originating
from natural sources, semisynthesis, or purely synthetic
methods, have been shown to display remarkable medicinal
properties.1−3 For instance, due to the restriction of their
conformational freedom, certain macrocyclic structures possess
an enhanced binding selectivity to speciﬁc biological targets.4
Rapamycin and its derivatives, so-called rapalogs, represent a
classical example of highly selective macrocyclic inhibitors.
They have the capacity to selectively bind and block the kinase
activity of the multiprotein complex mTORC1 without
aﬀecting the parented mTORC2.5 Additionally, macrocycliza-
tion has become an essential method to reduce polarity and
enhance the proteolytic stability of biologically active
peptides.1 Attracted by these beneﬁts, medicinal chemists
have recently incorporated the design of macrocyclic rings
from nitrogen-rich heterocyclic cores into their toolbox of lead
optimization approaches.1−4,6,7 As a result, several macro-
cyclization strategies reported in the literature have resulted in
potent and selective kinase inhibitors,8−11 including the
recently approved antineoplastic drug lorlatinib.12
Encouraged by the bioactive properties of the pyrazolopyr-
imidine derivative eSM119,13 a compound that displays
inhibitory activity against three oncogenic receptor tyrosine
kinases (AXL, FLT3, and RET, with IC50 values of 0.40, 0.53,
and 0.60 μM, respectively), the development of an 18-atom
macrocyclic derivative of this compound was investigated (see
Figure 1).
■ RESULTS AND DISCUSSION
A nonsymmetrical dimer-macrocyclization strategy based on a
double-copper(I)-catalyzed alkyne−azide cycloaddition
(CuAAC) reaction was applied for the construction of
macrocycle 1 from commercially available 6-chloro-1H-
pyrazolo[3,4-d]pyrimidine, 2. The full synthetic route is
described in Scheme 1 and the Experimental Section. Brieﬂy,
iodination at the C3 position was carried out with N-
iodosuccinimide (76%), followed by alkylation with propargyl
bromide (46%) to incorporate the ﬁrst alkyne group.
Subsequently, the chloro atom at the C6 position of 4 was
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substituted via a SNAr reaction
14 with propargylamine in
tetrahydrofuran (THF) to introduce a second alkyne handle
on the pyrazolo[3,4-d]pyrimidine core, giving rise to
compound 5 in good yield (80%). The assembly of dialkyne
5 with 1,3-bis(azidomethyl)benzene 6 was achieved using
copper iodide, sodium ascorbate, and triethylamine15 to give
rise to macrocycle 7 in 23% yield. Since the modest reaction
yield obtained was suﬃcient to progress to the next step of the
route, reaction conditions were not optimized further. The
synthesis of the macrocyclic analogue of eSM119, that is,
compound 1, was completed by the palladium-catalyzed cross-
coupling of 7 with 6-(4-Boc-piperazinyl)pyridyl-3-boronic acid
pinacol ester, 8, followed by Boc deprotection under acidic
conditions (51% yield for two steps).
NMR studies of compounds 7, 9, and 1 provided insights
into the conformational dynamics of this novel macrocyclic
construct. An extremely broad doublet was observed from 4 to
5.2 ppm in the spectra of the three compounds (Figure S1 of
the Supporting Information, highlighted by a frame). This ﬂat-
looking signal, which was identiﬁed as the methylene group
bonded to the amino group at the C6 position, is indicative of
numerous conformers coexisting at the ambient temperature.16
These conformers can present the methylene protons oriented
toward slightly diﬀerent chemical surroundings, thus inducing
diﬀerent shieldings and consequently diﬀerent chemical shifts.
The presence of multiple conformers is in agreement with in
silico calculations obtained with MacroModel,17 which yielded
155 conformers that can be classiﬁed into four main groups
(see Figure 2 and Supporting. Information).
Next, 1H NMR analysis of 1 was performed over a range of
temperatures (27, 40, 60, and 80 °C), aiming to overcome the
rotational energy barrier and increase the rate of exchange
between the conformers. As shown in Figure 3A, the NMR
spectra show the coalescence of the signals as the temperature
increases, eventually merging into a single averaged peak at
4.64 ppm that integrates for two protons. Given the moderate
temperature required for conformer interconversions (single
peak starts to form at 40 °C), it is expected that under
physiological conditions, compound 1 could exchange between
conformers to potentially ﬁnd energetically favorable con-
Figure 1. Structure and synthesis/retrosynthetic strategy of eSM119
(left) and macrocycle 1 (right). The novel compound 1 was designed
by the incorporation of a second triazole group to enclose the
cyclophene ring.
Scheme 1. Synthesis of the 18-Atom Macrocycle 1 from 6-
Chloro-1H-pyrazolo[3,4-d]pyrimidine, 2
Figure 2. Representative three-dimensional (3D) structure models
(superimposed through the pyrazolopyrimidine ring) of four of the
most signiﬁcant types of conformers found for 1 after macrocyclic
sampling with MacroModel.
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formations that increase cell permeability and/or binding to
target proteins in an eﬀective manner.
The methylene peak annotation was corroborated by a 2D
heteronuclear single-quantum correlation (HSQC) analysis
(Figure 3B,C). Although no carbon−proton coupling was seen
at 27 °C, a strong correlation between the carbon peak at 36.7
ppm of the 13C NMR spectrum and the proton signal at 4.64
ppm was clearly observed when the experiment was performed
at 80 °C.
Given the structural and conformational diﬀerences between
macrocycle 1 and its open analogue eSM119 (see Figure 1),
the biological properties of 1 were expected to diﬀer from
those of eSM119. To evaluate this, biochemical assays were
performed to test the capacity of 1 to inhibit the enzymatic
activity of a selection of closely related protein kinases: TAM
family members TYRO3, AXL, and MER and receptor tyrosine
kinases RET and FLT3. This focused panel of kinases was
selected based on the reported selectivity proﬁle of eSM119.13
Enzymatic studies (based on 33P incorporation) were
performed by Reaction Biology Corp. using a 10-point semi-
log dilution series.18 The calculated IC50 values are compiled in
Table 1.
The study revealed that compound 1 moderately inhibits
AXL kinase with an IC50 value of 13 μM. Notably, it did not
elicit the inhibition of TYRO3, MER, and RET (estimated IC50
> 1 mM) and exhibited an IC50 value of 53.5 μM for FLT3, a
potency over 4-fold lower than that against AXL. The
inhibitory properties of macrocycle 1 clearly contrast with
the similar levels of activity displayed by eSM119 for AXL and
kinases FLT3 and RET (1.3- and 1.5-fold diﬀerences,
respectively). Thus, the large diﬀerence in activity displayed
by macrocycle 1 against AXL and RET, with IC50 values
diﬀering by >75-fold, is particularly relevant. The improved
selectivity proﬁle of 1 is important because, despite many
eﬀorts, the development of selective AXL inhibitors has proved
to be extremely challenging, with no selective inhibitors of
AXL kinase activity reported to date.19 This includes
bemcentinib, an orally available kinase inhibitor in clinical
development that is marketed as an AXL-selective inhibitor,19
although it has been shown by several groups to equally inhibit
FLT3 and other kinases.13,20,21 To the best of our knowledge,
compound 1 (eOC148) is the ﬁrst one to display distinctly
superior activity for AXL compared to its most closely related
kinases MER, RET, and FLT3. However, it is also important to
note that the herein reported macrocyclization strategy
negatively impacted the potency of the analog to inhibit
AXL relative to the open conformation (32.5-fold reduction in
potency), indicating that there is still room for improvement.
To shed light on the preferential inhibition of AXL over
RET, docking studies were conducted using the available
crystal structures of the proteins (PDB entries: 5U6B22 and
2IVV,23 respectively). Computational strategy and analyses are
described in full in the Supporting Information. The 155
conformational structures of 1 yielded by MacroModel
sampling were docked at the active site of the AXL kinase
domain using Autodock 4.2.6.24 As shown in Figure 4A, the
predicted binding pose of compound 1 displays the piperazino-
pyridinyl branch oriented toward a negatively charged region
(in red) corresponding to the glycine-rich G-loop of the N-
lobe (see Supporting Information). The positively charged
piperazine (protonated at physiological pH) forms a H-bond
with Gly545 in one of the most ﬂexible parts of the N-lobe,
responsible for positioning the γ-phosphate of ATP for
catalysis (Supporting Information, Figure S4). Moreover, its
newly incorporated triazole ring faces the Asp690 residue of
the DFG motif and the catalytically essential Lys567, with
which it forms two H-bonds. Together with the H-bond
Figure 3. (A) 1H NMR spectra of 1 at diﬀerent temperatures. (B, C)
two-dimensional (2D) HSQC analysis of 1 at 27 and 80 °C.
Table 1. IC50 Values (in μM) for 1 and eSM119 against a
Selection of Recombinant Tyrosine kinases
AXLa TYRO3a MERa RET FLT3
1 13.0 >1000 >1000 >1000 53.5
eSM119 0.40 >10 2.3 0.60 0.53
aMember of the TAM subfamily.
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formed by the piperazine ring with the backbone chain of the
G-loop, these interactions support the capacity of compound 1
to inhibit AXL kinase activity.
Analogous docking studies were also performed with the
crystal structure of RET kinase (PDB entry: 2IVV).23 The
predicted binding pose of 1 is orientated in a fashion similar to
that in AXL; however, the formation of H-bonds with Lys567
are precluded due to a more tightened disposition of the ATP-
binding cleft that forces the ligand to move slightly away from
the Lys567 residue. This pose indicates a lower binding
aﬃnity, thus providing the rationale for the preferential binding
of compound 1 to AXL kinase over RET.
Finally, the antiproliferative properties of 1 were tested
across a panel of eight cell lines: breast cancer MDA-MB-231,
ZR-75-1, and MCF7, glioma U87, colorectal cancer HCT116,
lung adenocarcinoma A549, and leukemia MOLM-13 and
MV4−11 cells. Cells were treated with compound 1 at 30 μM
for 5 days, and the cell viability was determined using the
PrestoBlue reagent. As shown in Figure 4B, compound 1
displayed antiproliferative activity against MV4−11 cells, but
not against the other cancer cell lines. This is important
because MV4−11 is an acute myeloid leukemia cell line that
has shown to be dependent on AXL signaling for survival.25 To
conﬁrm this, MV4−11 cells were treated with macrocycle 1
over a range of concentrations (0.3−30 μM). The resulting
dose−response curve (see Supporting Information, Figure S7)
provided an half- maximal eﬀective concentration (EC50) value
of 16.6 μM. The fact that compound 1 displays anticancer
activity against a cell line that is reliant on AXL activity for
proliferation but not in non-AXL-dependent cancer cell lines
further highlights the selectivity proﬁle of this novel
compound. The similar potency of 1 against the recombinant
AXL protein (IC50 = 13 μM) and in MV4−11 cells (EC50 =
16.6 μM) indicates that this macrocyclic construct possesses a
high capacity to cross the cell membrane.
■ CONCLUSIONS
In conclusion, the synthesis and characterization of a novel 18-
atom macrocyclic structure comprising four concatenated rings
is herein reported. The construct was readily assembled using a
nonsymmetrical dimer macrocyclization strategy based on a
double CuAAC reaction. The macrocycle, which has been built
from a pyrazolopyrimidine scaﬀold, was designed to create a
conformationally constrained analog of the multikinase
inhibitor eSM119 and displayed moderate while selective
inhibition of AXL kinase, oﬀering a new optimization pathway
to block the activity of this cancer-associated protein kinase
with superior selectivity. Importantly, the reported synthetic
method provides a practical route for the combinatorial
generation of libraries of 18-atom macrocycles by varying the
benzene ring, the 6:5 fused heterocyclic core, and their
substituents, to explore additional chemical space with
pharmacological potential. The docking studies also suggest
that the on-target potency could be improved by locking the
structure at the right conformation. Future eﬀorts will be
focused on optimizing the structure substituents and the
macrocyclic ring size and conformational freedom, for example,
by switching the benzene ring to 5-membered heterocycles or
making homologs7 by eliminating one or more of the
macrocyclic CH2 groups.
■ EXPERIMENTAL SECTION
General Information. Chemicals were purchased from
Sigma-Aldrich or Fisher. NMR spectra were recorded at room
temperature (rt) on a 500 MHz Bruker Avance III
spectrometer, unless otherwise stated. Chemical shifts are
reported in ppm relative to the solvent peak. MS were obtained
in a Bruker MicroTOF II. Analytical thin-layer chromatog-
raphy (TLC) was performed using TLC Silica gel 60 F254
plates and visualized under a UV lamp. Puriﬁcations were
carried out by ﬂash chromatography using a silica gel 220−440
mesh (Sigma-Aldrich). Compounds used in the biological
experiments were >95% pure, as measured by high-perform-
ance liquid chromatography (HPLC) using an UV−vis 254 nm
detector. Method: eluent A: water and triﬂuoroacetic acid
(0.4%); eluent B: acetonitrile; A/B = 95:5 to 20:80 in 6 min,
isocratic 1 min, 20:80 to 95:5 in 0.1 min, and isocratic 2 min.
Stock solutions (100 mM) were prepared in dimethylsulph-
oxide (DMSO).
Synthesis of 6-Chloro-3-iodo-1-propargyl-1H-pyrazolo-
[3,4-d]pyrimidine (4). Compound 4 was synthesized by the
iodination of compound 2 into 6-chloro-3-iodo-1H-pyrazolo-
[3,4-d]pyrimidine (3), as previously described.11 Subsequently,
to a suspension of 3 (560 mg, 2 mmol) in anhydrous
dimethylformamide (DMF) (10 mL) at 0 °C under an argon
atmosphere was added sodium hydride 60% in mineral oil in
small amounts (120 mg, 3 mmol), followed by the dropwise
addition of a solution of propargyl bromide in toluene (80%
w/w in toluene, 0.32 mL, 3 mmol). The mixture was heated
under microwave irradiation at 150 °C for 1.5 h. The solvents
Figure 4. (A) Columbic surface representation of the AXL active site
with the predicted binding pose of 1 (light yellow). Red and blue
areas represent negatively and positively polarized areas, respectively.
(B) Antiproliferative activity of compound 1 (30 μM) against a panel
of cancer cell lines. The cell viability was analyzed with PrestoBlue at
day 5. Error bars: ± standard deviation (SD) from n = 2.
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were then evaporated, and the residue was redissolved with a
mixture of EtOAc (30 mL) and water (15 mL). The aqueous
layer was extracted twice with EtOAc (15 mL), and the
combined organic layers were dried with anhydrous Na2SO4,
ﬁltered, and evaporated. The crude extract was puriﬁed by ﬂash
chromatography using DCM as the eluent to aﬀord compound
413 as a white solid (293 mg, 46%). 1H NMR (500 MHz,
CDCl3) δ 8.80 (s, 1H), 5.26 (d, J = 2.5, 2H), 2.44 (t, J = 2.5,
1H).
Synthesis of 3-Iodo-N,1-dipropargyl-1H-pyrazolo[3,4-d]-
pyrimidine-6-amine (5). To a solution of 4 (800 mg, 2.5
mmol) in THF (15 mL) was added propargylamine (0.72 mL,
11.32 mmol) dropwise. The mixture was heated at 120 °C
under microwave irradiation for 1 h. The solvent was
evaporated, and the crude extract was puriﬁed by recrystalliza-
tion from MeOH to aﬀord compound 5 as a beige solid (600
mg, 80%). 1H NMR (500 MHz, DMSO-d6) δ 8.56 (m, 1H),
8.16 (bs, 1H), 5.06 (s, 2H), 4.17 (dd, J = 6.0, 2.5, 2H), 3.38 (t,
J = 2.5, 1H), 3.06 (s, 1H). 13C{1H} NMR (126 MHz, DMSO-
d6) δ 161.6, 155.1, 154.8, 112.8, 94.1, 81.9, 78.7, 76.0, 73.1,
35.9, 30.8. high-resolution mass spectrometry (HRMS)
[electrospray ionization-time of ﬂight (ESI-TOF)] m/z: [M
+ H]+ Calcd for C11H9IN5 337.9897; Found 337.9890.
Synthesis of 1,3-Bis(azidomethyl)benzene (6). Compound
6 was synthesized as previously described.26
Synthesis of 13-Iodo-11H,31H,71H-9-aza-1(1,6)-pyrazolo-
[3,4-d]pyrimidine-3(4,1),7(1,4)-ditriazole-5(1,3)-benzenecy-
clononaphane (7). To a solution of 5 (337 mg, 1 mmol) in
dioxane/H2O (20/3 mL) was added a solution of 6 (188 mg, 1
mmol), CuI (66 mg, 0.4 mmol), sodium ascorbate (40 mg, 0. 2
mmol), and triethylamine (TEA) (0.11 mL, 0.8 mmol) in
dioxane (1 mL). The mixture was stirred at room temperature
for 36 h. The solvent was evaporated, and the crude extract was
puriﬁed by ﬂash chromatography using DCM/MeOH 10/0.4
as the eluent to aﬀord a white solid (120 mg, 23%). 1H NMR
(500 MHz, DMSO-d6) δ 8.52 (s, 1H), 8.34 (t, J = 6.5, 1H),
7.71 (s, 1H), 7.55 (s, 1H, H), 7.41−7.33 (m, 3H), 6.95 (s,
1H), 5.58−5.33 (m, 6H), 5.12−4.04 (bd, 2H). 13C{1H} NMR
(126 MHz, DMSO-d6) δ 161.6, 155.0, 154.2, 146.5, 143.9,
137.0, 136.8, 129.0, 128.2, 128.1, 126.7, 122.0, 121.4, 112.4,
92.9, 52.6, 52.5, 41.9, 36.3. HRMS (ESI-TOF) m/z: [M + H]+
Calcd for C19H17IN11 526.0708; Found 526.0701.
Synthesis of 13-[6-(4-Boc-piperazin-1-yL)pyridin-3-yl]-
11H,31H,71H-9-aza-1(1,6)-pyrazolo[3,4-d]pyrimidin-3-
(4,1),7(1,4)-ditriazole-5(1,3)-benzenecyclononaphane (9).
To a suspension of 7 (58.5 mg, 0.11 mmol) in DMF/H2O
(5/0.5 mL) was added 6-(4-Boc-piperazin-1-yl)pyridine-3-
boronic acid pinacol ester (8, 65 mg, 0.17 mmol), sodium
carbonate (24 mg, 0.17 mmol), triphenylphosphine (6 mg,
20% mol), and palladium(II) acetate (2 mg, 5% mol). The
mixture was irradiated by microwave at 120 °C for 1 h. The
solvent was evaporated and the crude extract was puriﬁed by
ﬂash chromatography using DCM/MeOH 10/0.6 as the eluent
to aﬀord a white solid (40 mg, 55%). 1H NMR (500 MHz,
DMSO-d6) δ 9.15 (s, 1H), 8.74 (s, 1H), 8.26−8.05 (m, 2H),
7.72 (s, 1H), 7.53 (s, 1H), 7.44−7.31 (m, 3H), 6.95 (s, 2H),
5.48 (s, 6H), 5.03−3.96 (bd, 2H), 3.58 (s, 4H), 3.45 (s, 4H),
1.43 (s, 9H). 13C{1H} NMR (126 MHz, DMSO-d6) δ 160.8,
158.4, 155.3, 154.4, 154−0, 146.8, 145.7, 144.3, 141.4, 137.0,
136.9, 135.5, 129.0, 128.2, 128.0, 126.7, 121.9, 121.4, 117.8,
107.2, 105.1, 79.0, 52.6, 52.6, 44.2, 41.8, 36.2, 28.1. HRMS
(ESI-TOF) m/z: [M + H]+ Calcd for C33H37N14O2
661.3218; Found 661.3232.
Synthesis of 13-[6-(Piperazin-1-yL)pyridin-3-yl]-
11H,31H,71H-9-aza-1(1,6)-pyrazolo[3,4-d]pyrimidine-3-
(4,1),7(1,4)-ditriazole-5(1,3)-benzenecyclononaphane (1). A
solution of 9 (19 mg, 0.029 mmol) in triﬂuoroacetic acid
(TFA)/H2O (4/0.5 mL) was stirred at room temperature for 2
h. The solvent was evaporated, and the crude extract was
puriﬁed by reversed-phase chromatography using H2O/MeOH
(6/4) as the eluent to aﬀord a white solid (15 mg, 92%). 1H
NMR (27 °C) (500 MHz, DMSO-d6) δ 9.16 (s, 1H), 8.77 (s,
1H), 8.20 (s, 1H), 8.14 (d, J = 8.5, 1H), 7.72 (s, 1H), 7.54 (s,
1H), 7.37 (s, 3H), 7.02 (d, J = 8.5, 1H), 6.95 (s, 1H), 5.18−
4.02 (bd, 2H), 5.50 (s, 6H), 3.74 (s, 4H), 3.13 (s, 4H). 1H
NMR (80 °C) (500 MHz, DMSO-d6) δ 9.08 (s, 1H), 8.74 (s,
1H), 8.12 (d, J = 8.5, 1H), 7.85 (s, 1H), 7.55 (s, 1H), 7.38 (m,
4H), 6.99 (d, J = 8.5, 1H), 6.89 (s, 1H), 5.49 (s, 6H), 4.64 (s,
2H), 3.76 (s, 4H), 3.15 (s, 4H). 13C{1H} NMR (126 MHz,
DMSO-d6) δ 160.8, 158.0, 155.3, 154.4, 146.8, 145.6, 144.2,
141.3, 137.0, 136.9, 135.7, 129.0, 128.2, 128.0, 126.6, 121.9,
121.4, 118.4, 107.4, 105.1, 52.6, 52.5, 43.1, 42.5, 41.8, 36.2.
HRMS (ESI-TOF) m/z: [M + H]+ Calcd for C28H29N14
561.2694; Found 561.2659.
Kinase Screening Assay. The radioisotope-based assay
([γ-33P]-ATP) consisted of measuring 33P incorporation
induced by each kinase (AXL, TYRO3, MER, RET, or
FLT3) on the substrate poly [Glu, Tyr] 4:1 in the presence of
eSM119 and compound 1 relative to DMSO. Experiments
were performed by Reaction Biology Corp.. Compounds’ IC50
values were determined from 1:3 dilution curves starting at 10
μM (10 points in total) with 10 μM ATP.
Cell Viability Assays. MDA-MB-231, MCF7, U87,
HCT116, and A549 cells were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum and 2 mM L-glutamine and incubated in a
Heracell 240i tissue culture incubator at 37 °C and 5% CO2.
ZR-75-1, MOLM-13, and MV4-11 cells were grown under the
same conditions with Roswell Park Memorial Institute (RPMI)
instead of DMEM. Cells were plated in 96-well plates at 1500
(HCT116 and A549), 2000 (MDA-MB-231, MCF7, and
U87), or 4000 cells/well (MOLM-13 and MV4−11 cells) in
95 (suspension cells) or 100 μL (for adherent cells) of
supplemented medium. Adherent cells were incubated for 48 h
in an incubator at 37 °C and 5% CO2. The media was then
aspirated from each well and replaced with 95 μL of fresh
medium. Suspension cells were treated on the same date that
they were seeded. Then, 5 μL of a DMSO solution of
compound 1 at 600 μM was added to each well containing
cells to obtain a ﬁnal concentration of 30 μM. Untreated cells
were incubated with DMSO (0.1% v/v). After 5 d, the
PrestoBlue cell viability reagent (10 μL) was added to each
well, and the plates incubated for 0.5−4 h (MV4−11 required
3 h of incubation). Fluorescence emission was detected using
an Envision ﬂuorescence plate reader (excitation 540 nm,
emission 590 nm). All conditions were normalized to the
untreated cells (100%). For the dose−response study, MV4−
11 cells were seeded in 96-well plates as described before.
Serial 1:3 dilutions of compound 1 in DMSO were prepared in
a separate 96-well intermediate plate. Then, 5 μL from the
intermediate plate was added to each well containing cells. The
determination of cell viability was performed at day 5 as
described before, and the results were normalized to the
untreated cells (100%). Curves were ﬁtted using a four-
parameter logistic ﬁt with the minimum value constrained to
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zero using the GraphPad Prism software to calculate EC50
values.
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